Evidence map›Paper›PMID 38267934›Full record

ArticleBMC cancer2024

Perioperative outcomes and continence following robotic-assisted radical cystectomy with mainz pouch II urinary diversion in patients with bladder cancer.

Suoshi Jing, Enguang Yang, Zuoxi Luo, Yunxin Zhang, Hui Ding, Li Yang, Zhilong Dong, Panfeng Shang, Zhongjin Yue, Gongjin Wu and 5 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Suoshi Jing *Institute of Urology, Key Laboratory of Gansu Province for Urological Diseases, Lanzhou University Second Hospital, Gansu Nephro-Urological Clinical Center, 730030, Lanzhou, China.
Enguang Yang *Institute of Urology, Key Laboratory of Gansu Province for Urological Diseases, Lanzhou University Second Hospital, Gansu Nephro-Urological Clinical Center, 730030, Lanzhou, China.
Zuoxi LuoInstitute of Urology, Key Laboratory of Gansu Province for Urological Diseases, Lanzhou University Second Hospital, Gansu Nephro-Urological Clinical Center, 730030, Lanzhou, China.
Yunxin ZhangInstitute of Urology, Key Laboratory of Gansu Province for Urological Diseases, Lanzhou University Second Hospital, Gansu Nephro-Urological Clinical Center, 730030, Lanzhou, China.
Hui DingInstitute of Urology, Key Laboratory of Gansu Province for Urological Diseases, Lanzhou University Second Hospital, Gansu Nephro-Urological Clinical Center, 730030, Lanzhou, China.
Li YangInstitute of Urology, Key Laboratory of Gansu Province for Urological Diseases, Lanzhou University Second Hospital, Gansu Nephro-Urological Clinical Center, 730030, Lanzhou, China.
Zhilong DongInstitute of Urology, Key Laboratory of Gansu Province for Urological Diseases, Lanzhou University Second Hospital, Gansu Nephro-Urological Clinical Center, 730030, Lanzhou, China.
Panfeng ShangInstitute of Urology, Key Laboratory of Gansu Province for Urological Diseases, Lanzhou University Second Hospital, Gansu Nephro-Urological Clinical Center, 730030, Lanzhou, China.
Zhongjin YueInstitute of Urology, Key Laboratory of Gansu Province for Urological Diseases, Lanzhou University Second Hospital, Gansu Nephro-Urological Clinical Center, 730030, Lanzhou, China.
Gongjin WuInstitute of Urology, Key Laboratory of Gansu Province for Urological Diseases, Lanzhou University Second Hospital, Gansu Nephro-Urological Clinical Center, 730030, Lanzhou, China.
Junsheng BaoInstitute of Urology, Key Laboratory of Gansu Province for Urological Diseases, Lanzhou University Second Hospital, Gansu Nephro-Urological Clinical Center, 730030, Lanzhou, China.
Junqiang TianInstitute of Urology, Key Laboratory of Gansu Province for Urological Diseases, Lanzhou University Second Hospital, Gansu Nephro-Urological Clinical Center, 730030, Lanzhou, China.
Jiaji WangInstitute of Urology, Key Laboratory of Gansu Province for Urological Diseases, Lanzhou University Second Hospital, Gansu Nephro-Urological Clinical Center, 730030, Lanzhou, China.
Nan XiaoInstitute of Urology, Key Laboratory of Gansu Province for Urological Diseases, Lanzhou University Second Hospital, Gansu Nephro-Urological Clinical Center, 730030, Lanzhou, China.
Zhiping WangInstitute of Urology, Key Laboratory of Gansu Province for Urological Diseases, Lanzhou University Second Hospital, Gansu Nephro-Urological Clinical Center, 730030, Lanzhou, China. wangzplzu@163.com.
Lanzhou University · CNLanzhou University Second Hospital · CN

Funding

National Natural Science Foundation of China 81874088
6 · The paper itself

Abstract

purposeTo present the widely unknown perioperative outcomes and continence status of bladder cancer patients following robotic-assisted radical cystectomy (RARC) with Mainz pouch II urinary diversion (UD). MATERIALS AND

methodsFrom November 2020 to December 2023, 37 bladder cancer patients who underwent RARC with Mainz pouch II UD were retrospectively assessed (ChiCTR2300070279). The results, which included patient demographics, perioperative data, continence, and complications (early ≤ 30 days and late ≤ 30 days) were reported using the RC-pentafecta criteria. RC-pentafecta criteria included ≥ 16 lymph nodes removed, negative soft tissue surgical margins, absence of major (Grade III-IV) complication at 90 days, absence of clinical recurrence at ≤ 12 months, and absence of long-term UD-related sequelae. A numeric rating scale assessed patient satisfaction with urinary continence 30 days after surgery. The validated Patient Assessment of Constipation Symptoms (PAC-SYM) questionnaire was used to evaluate bowel function. The Kaplan-Meier curve was used to evaluate overall survival (OS).

resultsOf the 37 patients evaluated over a median (range) follow-up period of 23.0 (12.0-36.5) months. The median (range) age was 65 (40-81) years. The median (range) time to urinary continence after surgery was 2.3 (1.5-6) months. Of the 37 patients, 31 (83.8%) were continent both during the day and at night, 34 (91.9%) were continent during the day, 32 (86.5%) were continent at night, 35 (94.6%) were satisfied with their urinary continence status, and 21 (56.8%) were very satisfied. The mean (range) voiding frequency was 6 (4-10) during the day and 3 (2-5.5) at night. The mean (range) PAC-SYM total score was 9.50 (4.00-15.00). In 12 (32.4%) of the patients, RC-pentafecta was achieved, and achieving RC-pentafecta was linked to better satisfaction scores (7.3 vs. 5.5, p = 0.034). There was no significant difference between RC-pentafecta and No RC-pentafecta groups in terms of OS (25.6 vs. 21.5 months, p = 0.16). 7 (19.4%) patients experienced late complications.

conclusionsMainz pouch II UD following RARC in bladder cancer patients results in a satisfactory continence rate. Achieving RC-pentafecta was correlated with better satisfaction scores. The intracorporeal approach to Mainz pouch II UD is beneficial for female patients due to its reduced invasiveness.

trial registrationChiCTR2300070279; Registration: 07/04/2023, Last updated version: 01/06/2023. Retrospectively registered.

Indexed as

Abdominal WallRobotic Surgical ProceduresUrinary Bladder NeoplasmsUrinary DiversionAgedAged, 80 and overConstipationCystectomyDisease ProgressionFemaleHumansBladder cancerContinenceMainz pouch IIRobotic-assisted radical cystectomyUrinary diversion

Identifiers

PMID38267934
PMCPMC10809619
OpenAlexW4391175603

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.